Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age

Vaccine

Volumn 29, Issue 12, 2011, Pages 2272-2278

  Baxter, R ^a   Patriarca, P A ^b   Ensor, K ^a   Izikson, R ^c   Goldenthal, K L ^d   Cox, M M ^c  

^a KAISER PERMANENTE   (United States)

^b BIOLOGICS CONSULTING GROUP INC   (United States)

^c Protein Sciences Corp   (United States)

^d Independent Consultant   (United States)

Author keywords

Baculovirus; Comparative immunogenicity; Hemagglutinin; Influenza vaccine; Recombinant

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BACULOVIRUS; CHILL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SHIVERING; SINGLE BLIND PROCEDURE; SYSTEMIC DISEASE; VIRUS CULTURE; VIRUS RECOMBINANT;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

EID: 79951812398     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.039     Document Type: Article

References (19)

1. Katz J.M., Webster R.G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989, 160:191-198.
2. Katz J.M., Wang M., Webster R.G. Direct sequencing of the HA gene of influenza (H3N2) reveals sequence identity with mammalian cell-grown virus. J Virol 1990, 64:1808-1811.
3. Chen Z., Zhou H., Jin H. The impact of key amino acid substitutions in the hemagglutinin. F influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine 2010, (April). [Epub ahead of print].
4. Simonsen L., Reichert T.A., Viboud C., Blackwelder W.C., Taylor R.J., Miller M.A. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005, 165:265-272.
5. Simonsen L., Taylor R.J., Viboud C., Miller M.A., Jackason L.A. Mortality benefits of influenza vaccination in elderly people: and ongoing controversy. Lancet Infect Dis 2007, 7:658-666.
6. Powers D.C., Smith G.E., Anderson E.L., Kennedy D.J., Hackett C.S., Wilkinson B.E., et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well-tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995, 171(6):1595-1598.
7. Treanor J.J., Betts R.F., Smith G.E., Anderson E.L., Hackett C.S., Wilkinson B.E., et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis 1996, 173(6):1467-1470.
8. Lakey D.L., Treanor J.J., Betts R.F., Smith G.E., Thompson J., Sannella E., et al. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis 1996, 174:838-841.
9. Powers D.C., McElhaney J.E., Florendo O.A.J., Manning M.C., Upshaw C.M., Bentley D.W., et al. Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. J Infect Dis 1997, 175:342-351.
10. Powers D.C., Smith G.E., Anderson E.L., Kennedy D.J., Hackett C.S., Wilkinson B.E., et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995, 171:1595-1599.
11. Treanor J.J., Schiff G.M., Couch R.B., Cate T.R., Hay C.M., She D., et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006, 193:1223-1228.
12. Treanor J.J., Schiff G.M., Hayden F.G., Brady R.C., Hay C.M., Meyer A.L., et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine. JAMA 2007, 297:1577-1582.
13. ® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 2009, 27:6589-6594. [EPub Vaccine, August 27, 2009].
14. Keitel W.A., Treanor J.J., El Sahly H.M., Gilbert A., Meyer A.L., Patriarca P.A., et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIV) among persons ≥65 years old. Vaccine 2009, 28:379-385.
15. CBER/FDA guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines (May 2007). http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf.
16. American Academy of Pediatrics Active immunization. 2006 Red book: report of the committee on infectious diseases 2006, American Academy of Pediatrics, Elk Grove Village, IL. 27th ed. L.K. Pickering (Ed.).
17. Braun M.M., Patriarca P.A., Ellenberg S.S. Syncope after immunization. Arch Pediatr Adolesc Med 1997, 151(3):255-259.
18. Keitel W.A., Atmar R.L., Cate T.R., Petersen N.J., Greenberg S.B., Ruben F. Couch RB. Safety of high dose of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006, 166:1121-1127.
19. Safdar A., Rodriguez M.A., Fayad L.E., Rodriguez G.H., Pro B., Wang M., et al. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin's lymphoma. J Infect Dis 2006, 194:1394-1397.